TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05057741

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multimodal prehabilitation
Description: Patients who will receive a multimodal prehabilitation program consisting of guided self-care activities at home that include exercise, nutrition and relaxation. Information Will be share by e health. Monitored by telephone daily during the first week and three times a week between the second and fourth week.~The final evaluation of the program will be performed one working day after the control appointment with surgery, which will be scheduled ten days after hospital discharge; and the satisfaction survey will be applied. At 30 days after surgery, a telephone follow-up will be made to inquire about complications and mortality. On that day, self-care recommendations will be given.
Study: NCT05362331

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Web Application
Description: Internet based application
Study: NCT05447598

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nurse-led remote monitoring program
Description: Symptoms of disease progression, clinical parameters, medication adherence and follow-up needs will be reported by patients or with support from relatives or homecare nurses 2-4 times/months over a three months period using a digital platform. Telephone monitoring is planned for patients who are not able to comply with the digital platform. In addition, an individualized self-treatment plan for diuretics and lifestyle advice will be prepared, preferably together with relatives at the outpatient clinic. Participants will also have access to a website with written information and videos about HF and self-management. Finally, a pillbox will be delivered to facilitate drug adherence.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care treatment
Description: Usual care treatment and follow-up care at the outpatient clinic and in primary care
Study: NCT05161637

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLC590
Description: TLC590 490mg or 588mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLC590
Description: TLC590 490mg or 588mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacain
Description: Bupivacaine 75mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Ropivacaine 150mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline 20mL or 24mL
Study: NCT06455436

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard healing abutment
Description: Participants will undergo a surgery to place an immediate klockner dental implant and will be receive a standard healing abutment

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Individualized healing abutment
Description: Participants will undergo a surgery to place an immediate klockner dental implant and will be receive an individualized healing abutment
Study: NCT05424991

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: comedy movie group
Description: The patients watched the collage videos of Turkish cinema Yeşilçam comedy films created by the researchers for 25 minutes. The videos were created by making collages from videos on youtube.
Study: NCT06105203

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Robotic-assisted total mesorectal excision
Description: TME will be performed with the assistance of robot in rectal cancer

Intervention type: PROCEDURE
Group type: OTHER
Intervention: laparoscopic-assisted total mesorectal excision
Description: TME will be performed with the assistance of laparoscopy in rectal cancer
Study: NCT04886193

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FLOT(Docetaxel+oxaliplatin+leucovorin+5-FU), Treprizumab, Tiggio capsule (S-1)
Description: * FLOT: Docetaxel 50mg/m2 ivd d1 + oxaliplatin 85mg/m2 ivd d1 + leucovorin 200mg/m2 ivd d1 + 5-FU 2600mg/m2 civ 24h Q2W~* Treprizumab 3mg/kg, intravenously administered on the first day of each cycle, Q2W~* Tiggio capsule (S-1) 40-60mg (BSA\<1.25 m2: 40mg, 1.25 m2≤BSA≤1.5 m2: 50mg, BSA\> 1.5 m2: 60mg) po bid d1-14 Q3W, continuous treatment for 1 year;~* Teriprizumab 240mg, intravenously, given on the first day of each cycle, Q3W, continuous treatment for 1 year.
Study: NCT05511025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6234
Description: Participants will receive a single dose of AZD6234 as a solution via SC or IV injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6234
Description: Participants will receive a single dose of AZD6234 as a solution via SC or IV injection
Study: NCT05103423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Multiple IV infusions of Placebo Injection diluted in sodium chloride

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Multiple IV infusions of Placebo Injection diluted in sodium chloride
Study: NCT05511025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6234
Description: Participants will receive a single dose of AZD6234 as a solution via SC or IV injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6234
Description: Participants will receive a single dose of AZD6234 as a solution via SC or IV injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6234
Description: Participants will receive a single dose of AZD6234 as a solution via SC or IV injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6234
Description: Participants will receive a single dose of AZD6234 as a solution via SC or IV injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6234
Description: Participants will receive a single dose of AZD6234 as a solution via SC or IV injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6234
Description: Participants will receive a single dose of AZD6234 as a solution via SC or IV injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching volumes of the placebo as a solution via SC or IV injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching volumes of the placebo as a solution via SC or IV injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching volumes of the placebo as a solution via SC or IV injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching volumes of the placebo as a solution via SC or IV injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching volumes of the placebo as a solution via SC or IV injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching volumes of the placebo as a solution via SC or IV injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching volumes of the placebo as a solution via SC or IV injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching volumes of the placebo as a solution via SC or IV injection

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Participants will receive a single dose of acetaminophen as part of a meal

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Participants will receive a single dose of acetaminophen as part of a meal
Study: NCT05874141

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: HBA1C
Description: blood sample on EDTA
Study: NCT05511025

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Participants will receive a single dose of acetaminophen as part of a meal
Study: NCT05874141

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Lipid profile, including total, LDL, and HDL cholesterol and Triglycerides
Description: serum sample

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Urine analysis and urinary albumin-to-creatinine ratio
Description: Morning urine sample

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Serum creatinine and estimated glomerular filtration rate
Description: serum sample

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Complete blood count
Description: blood sample on EDTA

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Thyroid-stimulating hormone
Description: serum sample

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Serum iron, TIBC, Transferrin saturation and serum ferritin if needed
Description: serum sample
Study: NCT04629261

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Use of ECOBICI (public bicycle sharing program)
Description: Use of ECOBICI program with and without incentive.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Use of ECOBICI (public bicycle sharing program)
Description: Use of ECOBICI program with and without incentive.
Study: NCT06067321

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: abdominal ultrasound, insertion of naso-gastric tube
Description: measurement antral cross sectional area, volume and pH of residual stomach contents

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: abdominal ultrasound, insertion of naso-gastric tube
Description: measurement antral cross sectional area, volume and pH of residual stomach contents
Study: NCT04729192

Intervention type: OTHER
Intervention: ObsQoR-10T Questionnaire
Description: The ObsQoR-10T questionnaire consists of 10 items assessing physical comfort and pain, physical independence, and emotional status. Each item is scored from 0 to 10 and the total score is the sum of the score for each item, which is a score from 0 to 110.
Study: NCT05882279

Intervention type: OTHER
Intervention: No Intervention
Description: This is a non-interventional study.
Study: NCT05617937

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Massage
Description: The connective tissue massage was started from the lumbosacral region (baseline) and was applied to the lower thoracic, scapular, inter-scapular and cervico-occipital region according to the vascular response of the connective tissue.
Study: NCT06219590

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Acetylcholine Iontophoresis
Description: Acetylcholine Iontophoresis 15 min/ three sessions/ week for two weeks.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Shame Acetylcholine Iontophoresis
Description: Shame Acetylcholine Iontophoresis 15 min/ three sessions/ week for two weeks.
Study: NCT05468788

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention: Integrative Community Therapy-based Psychodrama
Description: Participants produce theatre scenes depicting issues that they have experienced. Group leaders then use a guide to facilitate a discussion of participants' feelings, coping strategies, and sharing of local knowledge.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Control: Improvisational Theatre
Description: Participants play improvisational theatre games.
Study: NCT06309277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-1020
Description: N-methyl-D-aspartate (NMDA) receptor antagonist

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GM-1020
Description: N-methyl-D-aspartate (NMDA) receptor antagonist
Study: NCT06038799

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Caregiver Skills Training (CST)
Description: The investigators are comparing the relative efficacy of CST between a CST group led by clinicians trained and supervised remotely versus a group led by clinicians trained an supervised face-to-face.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Caregiver Skills Training (CST)
Description: The investigators are comparing the relative efficacy of CST between a CST group led by clinicians trained and supervised remotely versus a group led by clinicians trained an supervised face-to-face.
Study: NCT06320912

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The intraparenchymal portal vein covered stent
Description: The intraparenchymal portal vein covered stent, produced by Shanghai Shenqi Medical Technology Co., Ltd., is used for a transjugular approach. It establishes an artificial shunt between the hepatic vein and the main branches of the portal vein within the liver. This helps in reducing portal venous pressure and alleviating or improving the symptoms of portal hypertension and its complications, such as variceal bleeding, gastropathy, refractory ascites, and/or hepatic hydrothorax.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TIPS Covered Stent System GORE
Description: The GORE® VIATORR® Transjugular Intrahepatic Portosystemic Shunt (TIPS) Covered Stent consists of an implantable covered stent and a percutaneous delivery catheter.
Study: NCT05789719

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: STEM-OA
Description: Combination of autologous or allogeneic MSC(AT)s and fat

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: STEM-OA
Description: Combination of autologous or allogeneic MSC(AT)s and fat

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: STEM-OA
Description: Combination of autologous or allogeneic MSC(AT)s and fat

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: STEM-OA
Description: Combination of autologous or allogeneic MSC(AT)s and fat

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: STEM-OA
Description: Combination of autologous or allogeneic MSC(AT)s and fat

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: STEM-OA
Description: Combination of autologous or allogeneic MSC(AT)s and fat
Study: NCT05499013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLN124
Description: SLN124 is a double-stranded small interfering ribonucleic acid (siRNA) targeting transmembrane protease, serine 6 (TMPRSS6) messenger ribonucleic acid (mRNA).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLN124
Description: SLN124 is a double-stranded small interfering ribonucleic acid (siRNA) targeting transmembrane protease, serine 6 (TMPRSS6) messenger ribonucleic acid (mRNA).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: sodium chloride, solution for injection
Study: NCT05757882

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 4 hours of fasting time
Description: Oral intake is not allowed for 4 hours before sedation including water.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 2 hours of fasting time
Description: Oral intake is not allowed for 2 hours before sedation including water.
Study: NCT05663190

Intervention type: OTHER
Intervention: mental foramen location
Description: location of mental foramen in relation to primary molars
Study: NCT05607901

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus ointment
Description: tacrolimus is an immunosuppressive drug acting as an immunomodulator to assist manage acute flares and reducing the severity of future flares

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone 1% cream
Description: Topical corticosteroids (TCS) are the cornerstone for the management of AD to which other treatments are compared.
Study: NCT06376396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: albendazole and praziquantel
Description: Combination of albendazole plus praziquantel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albendazole
Description: Albendazole alone
Study: NCT05874141

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Electrocardiography (ECG)
Description: by electrocardiogram

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Transthoracic echocardiography, Neck ultrasonography if needed and abdominopelvic ultrasound
Description: imaging

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Arterial duplex ultrasound of both lower limbs
Description: imaging

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Random blood glucose
Description: serum sample

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: AST, ALT, albumin
Description: serum sample
Study: NCT04528238

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Relaxing Visual Immersion
Description: During the intravenous treatment for cancer, a nature movie will be projected on the ceiling of the room, along with natural sounds or a relaxing music. The patient will choose the movie or movies he wants to watch and can decide to stop the Relaxing Visual Immersion (RVI) at any time. The RVI is a system that does not isolate the patient from his familiar or medical entourage and which integrates virtual scenarios in the environment of care.
Study: NCT05951647

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chamomile extract mouthwash
Description: 5% chamomile extract mouthwash in a dose of 15 ml twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomegranate peel extract mouth wash
Description: 5% pomegranate peel extract mouth wash in a dose of 15 ml twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination of 5% chamomile extract and pomegranate peel extract mouthwash
Description: Use a combination of 5% chamomile extract and pomegranate peel extract mouthwash in a dose of 15 ml twice daily.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Scaling
Description: Patients will be managed by scaling

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Scaling and Chlorohexidine mouthwash
Description: scaling and will use 0.12%% chlorohexidine mouthwash in a dose of 15 ml twice daily.
Study: NCT05518461

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iThrive WI Intervention
Description: Participants will receive COVID-19 and overdose-related educational and motivational content over the course of 12 weeks through the Thrive4Life Connect, a mobile health application. They will be invited to set goals for lowering overdose and COVID-19 risk.
Study: NCT04802603

Intervention type: RADIATION
Group type: OTHER
Intervention: Spine stereotactic body radiotherapy
Description: Cohort 1 - De novo: Spine stereotactic body radiotherapy to a dose of 40 Gy in 5 fractions.~Cohort 2 - Prior radiotherapy: Risk-adapted spinal cord tolerance based on prior spine stereotactic body radiotherapy to a dose of 40 Gy in 5 fractions.
Study: NCT06026280

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DRIVEN Application
Description: Participants will complete the six-week DRIVEN program, which includes a smartphone application and job coaching.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Career Resources
Description: Participants will receive weekly information about job-searching skills and resources from a study coordinator for six weeks.
Study: NCT06135948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extra dose of L-thyroxine, 25 mcg during Ramadan
Description: Extra dose of L-thyroxine, 25 mcg during the month of Ramadan
Study: NCT06499714

Intervention type: OTHER
Intervention: Exposure to 3600 m
Description: Participants will travel to and stay for 2 days at an altitude of 3600 m.

Intervention type: OTHER
Intervention: Exposure to 3600 m
Description: Participants will travel to and stay for 2 days at an altitude of 3600 m.
Study: NCT06445257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zanubrutinib 160 mg BID orally
Description: The ZRMT induction and maintenance regimen
Study: NCT05806255

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The RELIEF App
Description: RELIEF is a virtual app designed for the remote self-reporting of symptoms in patients with palliative care needs. The patient/caregiver securely logs into the site and self-reports symptoms, distress, and pain using the validated clinical tools ESAS-r, Distress Thermometer (DT), and Brief Pain Inventory (BPI) currently in daily use by healthcare providers across Canada.~This data is reported to the healthcare providers via RELIEF. Any increases in symptom burden, distress, or pain are flagged for clinical review as RELIEF alerts. Healthcare providers received alerts via secure email for any sudden changes in symptom status, or if the patient's symptoms, distress, or pain severity increases by set amounts over a period of time. Following review of the RELIEF alert by the healthcare providers, patients receive (1) earlier intervention; (2) mobilization of auxiliary services; and (3) recommendation for urgent clinic/home visit or emergency department visit.
Study: NCT06515951

Intervention type: DIAGNOSTIC_TEST
Intervention: STANDING algorithm
Description: The STANDING algorithm is composed by four steps. The first phase consists in evaluating the presence of spontaneous nystagmus at rest for at least five minutes with and without Frenzel goggles in order to assess if a acute vestibular syndrome is present. If there is not a spontaneous nystagmus, then positional maneuvers (Pagnini-Mc Cure and Dix-Hallpike) have to be performed. Otherwise if spontaneous nystagmus is observed, its feature are fundamental to diagnose a central vertigo. If nystagmus characteristics suggest a peripheral form, the head impulse test is performed by instructing the patient to keep eyes on a fixed target and then turned the head quickly. An abnormal response is typical of vestibular neuritis. In any cases after the described maneuvers, the patient must be evaluated when standing up and walking: if this turn out to be impossibile, the test is indicative of central nervous system disease.
Study: NCT05674136

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INVSENSOR00061
Description: Noninvasive pulse oximeter sensor
Study: NCT05511025

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Participants will receive a single dose of acetaminophen as part of a meal

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Participants will receive a single dose of acetaminophen as part of a meal
Study: NCT05150678

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: removal of ceserean section scar
Description: we will remove the previous scar in group A

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: removal of ceserean section scar
Description: we will remove the previous scar in group A

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: non removal of cesearean section scar
Description: we will open in the previous cesearean scar in group B

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: non removal of cesearean section scar
Description: we will open in the previous cesearean scar in group B